The Efficacy of Intravitreal Conbercept for Chronic Central Serous Chorioretinopathy
Purpose. To evaluate the efficacy and safety of conbercept for patients with chronic central serous chorioretinopathy (CSC). Methods. A retrospective clinical study. Thirty-one patients (35 eyes) with chronic CSC were given intravitreal injections of conbercept and followed up for at least 6 months....
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2019/7409426 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563711595773952 |
|---|---|
| author | Jianbo Mao Caiyun Zhang Chenyi Liu Lijun Shen Jimeng Lao Yirun Shao Yiqi Chen Jiwei Tao |
| author_facet | Jianbo Mao Caiyun Zhang Chenyi Liu Lijun Shen Jimeng Lao Yirun Shao Yiqi Chen Jiwei Tao |
| author_sort | Jianbo Mao |
| collection | DOAJ |
| description | Purpose. To evaluate the efficacy and safety of conbercept for patients with chronic central serous chorioretinopathy (CSC). Methods. A retrospective clinical study. Thirty-one patients (35 eyes) with chronic CSC were given intravitreal injections of conbercept and followed up for at least 6 months. Observed indicators included best-corrected visual acuity (BCVA), central macular thickness (CMT), and resolution of subretinal fluid (SRF). Serial changes in BCVA and CMT were analyzed by using repeated measures analysis of variance. Results. During the 6-month follow-up, the mean number of injections required and performed was 1.77 ± 0.60. The logMAR BCVA was 0.48 ± 0.26 at the baseline, 0.34 ± 0.26, 0.30 ± 0.26, 0.27 ± 0.26, 0.24 ± 0.26, and 0.23 ± 0.26 at 2-week and 1-, 2-, 3-, and 6-month follow-ups, respectively (F = 27.173, P<0.05). CMT was 313.74 ± 144.51 μm at the baseline and decreased to 263.49 ± 120.44 μm, 225.91 ± 91.98 μm, 195.77 ± 66.69 μm, 189.74 ± 65.41 μm, and 199.49 ± 81.50 μm at 2-week and 1-, 2-, 3-, and 6-month follow-ups, respectively (F = 18.093, P<0.05). Full resolution of SRF was achieved in 8 (22.9%) eyes at 1 month, 16 (45.7%) eyes at 2 months, 22 (62.9%) eyes at 3 months, and 27 (77.1%) eyes at 6 months after the initial treatment of anti-VEGF injection. No severe adverse event was noted relevant to the therapy. Conclusions. Intravitreal injection of conbercept may effectively reduce the CMT and improve the BCVA in chronic CSC in a short term of 6 months. |
| format | Article |
| id | doaj-art-669cce13c067493dbcdd9651ff1a6343 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-669cce13c067493dbcdd9651ff1a63432025-02-03T01:12:51ZengWileyJournal of Ophthalmology2090-004X2090-00582019-01-01201910.1155/2019/74094267409426The Efficacy of Intravitreal Conbercept for Chronic Central Serous ChorioretinopathyJianbo Mao0Caiyun Zhang1Chenyi Liu2Lijun Shen3Jimeng Lao4Yirun Shao5Yiqi Chen6Jiwei Tao7Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaEye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaChicago College of Optometry, Midwestern University, Downers Grove, IL, USAEye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaEye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaEye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaEye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaEye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaPurpose. To evaluate the efficacy and safety of conbercept for patients with chronic central serous chorioretinopathy (CSC). Methods. A retrospective clinical study. Thirty-one patients (35 eyes) with chronic CSC were given intravitreal injections of conbercept and followed up for at least 6 months. Observed indicators included best-corrected visual acuity (BCVA), central macular thickness (CMT), and resolution of subretinal fluid (SRF). Serial changes in BCVA and CMT were analyzed by using repeated measures analysis of variance. Results. During the 6-month follow-up, the mean number of injections required and performed was 1.77 ± 0.60. The logMAR BCVA was 0.48 ± 0.26 at the baseline, 0.34 ± 0.26, 0.30 ± 0.26, 0.27 ± 0.26, 0.24 ± 0.26, and 0.23 ± 0.26 at 2-week and 1-, 2-, 3-, and 6-month follow-ups, respectively (F = 27.173, P<0.05). CMT was 313.74 ± 144.51 μm at the baseline and decreased to 263.49 ± 120.44 μm, 225.91 ± 91.98 μm, 195.77 ± 66.69 μm, 189.74 ± 65.41 μm, and 199.49 ± 81.50 μm at 2-week and 1-, 2-, 3-, and 6-month follow-ups, respectively (F = 18.093, P<0.05). Full resolution of SRF was achieved in 8 (22.9%) eyes at 1 month, 16 (45.7%) eyes at 2 months, 22 (62.9%) eyes at 3 months, and 27 (77.1%) eyes at 6 months after the initial treatment of anti-VEGF injection. No severe adverse event was noted relevant to the therapy. Conclusions. Intravitreal injection of conbercept may effectively reduce the CMT and improve the BCVA in chronic CSC in a short term of 6 months.http://dx.doi.org/10.1155/2019/7409426 |
| spellingShingle | Jianbo Mao Caiyun Zhang Chenyi Liu Lijun Shen Jimeng Lao Yirun Shao Yiqi Chen Jiwei Tao The Efficacy of Intravitreal Conbercept for Chronic Central Serous Chorioretinopathy Journal of Ophthalmology |
| title | The Efficacy of Intravitreal Conbercept for Chronic Central Serous Chorioretinopathy |
| title_full | The Efficacy of Intravitreal Conbercept for Chronic Central Serous Chorioretinopathy |
| title_fullStr | The Efficacy of Intravitreal Conbercept for Chronic Central Serous Chorioretinopathy |
| title_full_unstemmed | The Efficacy of Intravitreal Conbercept for Chronic Central Serous Chorioretinopathy |
| title_short | The Efficacy of Intravitreal Conbercept for Chronic Central Serous Chorioretinopathy |
| title_sort | efficacy of intravitreal conbercept for chronic central serous chorioretinopathy |
| url | http://dx.doi.org/10.1155/2019/7409426 |
| work_keys_str_mv | AT jianbomao theefficacyofintravitrealconberceptforchroniccentralserouschorioretinopathy AT caiyunzhang theefficacyofintravitrealconberceptforchroniccentralserouschorioretinopathy AT chenyiliu theefficacyofintravitrealconberceptforchroniccentralserouschorioretinopathy AT lijunshen theefficacyofintravitrealconberceptforchroniccentralserouschorioretinopathy AT jimenglao theefficacyofintravitrealconberceptforchroniccentralserouschorioretinopathy AT yirunshao theefficacyofintravitrealconberceptforchroniccentralserouschorioretinopathy AT yiqichen theefficacyofintravitrealconberceptforchroniccentralserouschorioretinopathy AT jiweitao theefficacyofintravitrealconberceptforchroniccentralserouschorioretinopathy AT jianbomao efficacyofintravitrealconberceptforchroniccentralserouschorioretinopathy AT caiyunzhang efficacyofintravitrealconberceptforchroniccentralserouschorioretinopathy AT chenyiliu efficacyofintravitrealconberceptforchroniccentralserouschorioretinopathy AT lijunshen efficacyofintravitrealconberceptforchroniccentralserouschorioretinopathy AT jimenglao efficacyofintravitrealconberceptforchroniccentralserouschorioretinopathy AT yirunshao efficacyofintravitrealconberceptforchroniccentralserouschorioretinopathy AT yiqichen efficacyofintravitrealconberceptforchroniccentralserouschorioretinopathy AT jiweitao efficacyofintravitrealconberceptforchroniccentralserouschorioretinopathy |